Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2020-12-07 5:08 pm Sale | 13D | SPERO THERAPEUTICS INC SPRO | GSK plc GSK | 1,740,606 6.4% | -78,872 (-4.33%) | View |
| 2020-09-22 6:51 pm Purchase | 13G | SPERO THERAPEUTICS INC SPRO | Aquilo Capital Management LLC | 4,497,142 17.4% | 3,342,786 (+289.58%) | View |
| 2020-06-04 5:03 pm Sale | 13D | SPERO THERAPEUTICS INC SPRO | GSK plc GSK | 1,819,478 8.8% | -114,528 (-5.92%) | View |
| 2020-02-14 7:57 pm Purchase | 13G | SPERO THERAPEUTICS INC SPRO | BIOTECHNOLOGY VALUE FUND L P | 2,028,405 9.99% | 213,259 (+11.75%) | View |
| 2020-02-14 4:40 pm Unchanged | 13D | SPERO THERAPEUTICS INC SPRO | GSK plc GSK | 1,934,006 10.1% | 0 (Unchanged) | View |
| 2020-02-13 8:22 pm Purchase | 13G | SPERO THERAPEUTICS INC SPRO | Aquilo Capital Management LLC | 1,154,356 6% | 122,409 (+11.86%) | View |
| 2020-02-04 2:56 pm Unchanged | 13G | SPERO THERAPEUTICS INC SPRO | Atlas Venture Fund IX L.P. | 1,376,968 7.2% | 0 (Unchanged) | View |
| 2020-01-31 4:20 pm Sale | 13G | SPERO THERAPEUTICS INC SPRO | Lundbeckfond Invest A/S | 877,489 4.6% | -214,285 (-19.63%) | View |